Monitor the upcoming FDA Type C meeting (Q3 2026) and any subsequent updates on Phase 2 trial initiation. The stock may see limited trading volume around clinical milestones given the early stage.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced Phase 1 data for TNX-4800, a monoclonal antibody for Lyme disease prevention, and outlined plans for an adaptive Phase 2 field study in the first half of 2027 pending FDA agreement. The Phase 1 data showed favorable safety and pharmacokinetics, but the filing is a routine pipeline update with no financial impact.
Key Facts
- TNX-4800 Phase 1 data presented at 4th Annual Ticks and Tickborne Diseases Symposium
- Phase 1 study showed no safety signals, rapid absorption, half-life 62-69 days
- Company plans to initiate adaptive Phase 2 field study in first half of 2027
- Type C meeting with FDA scheduled for early Q3 2026
- Two-dose subcutaneous regimen: spring dose + booster 2 months later
Financial Impact
No financial figures disclosed; clinical-stage biotech with no revenue impact from this update
Risk Factors
- FDA may not agree to the proposed Phase 2 design
- Phase 2 trial results may not demonstrate efficacy
- Competition from vaccines in development (e.g., Pfizer's Lyme vaccine)
- Company needs additional financing to fund trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999371-26-009289 |
| Exhibit: ex99-01.htm | 0001999371-26-009289 |
| Exhibit: ex99-02.htm | 0001999371-26-009289 |
| Document: 0001999371-26-009289-index-headers.html | 0001999371-26-009289 |
| Document: 0001999371-26-009289-index.html | 0001999371-26-009289 |
| Document: 0001999371-26-009289.txt | 0001999371-26-009289 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.39 (−5.93%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.39 (−16.04%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.39 (+33.21%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.39 (−49.10%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.39 (−59.04%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.39 (−49.48%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.39 (−48.02%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.39 (−53.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers